Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study
- PDF / 1,094,223 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 76 Downloads / 157 Views
RESEARCH ARTICLE
Open Access
Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007–2018) S. Cocchio1, G. M. Prandi2, P. Furlan1, C. Bertoncello1, M. Fonzo1, M. Saia3, T. Baldovin1 and V. Baldo1*
Abstract Background: Human papillomavirus (HPV) is a common sexually transmitted pathogen and the cause of several cancers and of anogenital warts. With this study, we estimated the trend of hospitalizations for anogenital warts (AGWs) in the Veneto region (Italy) from 2007 to 2018. Methods: The analysis included all the hospital discharge records of public and accredited private hospitals occurred in Veneto residents in the timespan 2007–2018. The ICD9-CM code 078.11 considered were those associated with condyloma acuminatum and those associated with surgical interventions for vulval/vaginal warts, penile warts anal warts. Annual total and sex- and age-specific hospitalization rates and trends were calculated and correlated with the different HPV vaccine coverage over the study period. Results: We observed an overall reduction of hospitalization rates for AGWs: from 15.0 hospitalizations every 100, 000 Veneto residents in years 2007–08 to 10.9 hospitalizations every 100,000 Veneto residents in year 2017–18 (− 37.4%; p < 0.05). Reduction has been caused by a drop in hospitalizations in females - from a rate of 20.4/100,000 in 2007–2008 to a rate of 10.8/100,000 in 2017–18 (AAPC: -7.1; 95%CI: − 10.6;-3.4); while in males, we observed a slight - but not statistically significant - increase in hospitalization rates. Conclusion: The marked decline in hospitalization rates for AGWs in Veneto Region is probably attributable to the high coverage rates of HPV vaccination programs implemented since 2008. Keywords: HPV, Hospitalization, Genital warts, Vaccination
Background Human papillomavirus (HPV) is one of the most frequently sexually transmitted viruses in the world. HPV infection plays a critical role in the pathogenesis of many forms of cancer (cervical, anal, vulvar, vaginal, penile, and head-neck cancers) as well as in the development of common dermatologic and sexually transmitted diseases, * Correspondence: [email protected] 1 Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padua, Padua, Italy Full list of author information is available at the end of the article
first of all condylomata acuminata or anogenital warts (AGWs) [1]. Anogenital warts cause a deep impact on the affected patient’s quality of life and their treatment requires, in some cases, hospitalization [2]. The first two vaccines (tetra-valent and bi-valent) designed to prevent papillomavirus-related diseases were licensed by European Medicines Agency (EMA) in 2006 and 2007 respectively, followed by the nine-valent vaccine licensed by EMA in 2015 [3]. In 2007, the Italian Minister of Health through its technical committee, Consiglio Superiore di Sanità, unanimously provided a positive
© The Author(s). 2020 Open Access This article is licensed
Data Loading...
